The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like
Cispaltin -> LiPlaCis®, Oxaliplatin -> LiPloxa.
The aim is to provide more effective treatment to cancer patients with fewer side effects.
LiPlasomes most advanced program is LiPlaCis® in a dose escalating clinical phase 1 trial. Please see www.clinicaltrials.gov.
A screening program to select “high likelihood responding patients” to be included in extension phase 1/phase 2 has been initiated.
LiPloxa is the most advanced pre-clinical program.